Kevin Sayer Sells 26,756 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $72.00, for a total value of $1,926,432.00. Following the completion of the sale, the insider directly owned 355,726 shares of the company’s stock, valued at $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 1.6%

Shares of NASDAQ DXCM traded up $1.19 during trading on Tuesday, hitting $73.57. The stock had a trading volume of 5,568,859 shares, compared to its average volume of 5,328,045. The firm has a fifty day moving average of $68.50 and a two-hundred day moving average of $68.23. The company has a market capitalization of $28.39 billion, a PE ratio of 31.44, a PEG ratio of 1.17 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the company earned $0.32 earnings per share. The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. As a group, equities research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Institutional investors have recently bought and sold shares of the company. Reflection Asset Management purchased a new stake in DexCom in the fourth quarter worth $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom during the 1st quarter valued at $25,000. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the last quarter. MCF Advisors LLC bought a new position in shares of DexCom during the 4th quarter worth $32,000. Finally, ORG Partners LLC grew its stake in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of a number of research analyst reports. UBS Group set a $95.00 target price on DexCom in a research note on Wednesday, June 10th. Barclays reiterated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. TD Cowen reissued a “buy” rating and issued a $95.00 price objective (up from $75.00) on shares of DexCom in a research report on Wednesday, June 10th. Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a research note on Monday, June 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of DexCom in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $84.88.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.